US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

5.90

+0.900018.00%

Post-market: 5.970.0700+1.19%19:42 EST

Volume:9.84K

Turnover:58.55K

Market Cap:53.47M

PE:-27.96

High:6.47

Open:5.00

Low:5.00

Close:5.00

52wk High:9.99

52wk Low:4.90

Shares:9.06M

Float Shares:3.98M

Volume Ratio:3.66

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2110

EPS(LYR):-0.2180

ROE:--

ROA:-106.39%

PB:-12.40

PE(LYR):-27.07

Loading ...

Overview Company News Filings

Amex Halt Add Info Lst 5.000000

THOMSON REUTERS

Nasus Pharma to Present at Oppenheimer Healthcare Life Sciences Conference

Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach

Nasus Pharma Ltd trading halted, volatility trading pause

Amex Halt Add Info Lst 6.400000

THOMSON REUTERS

Nasus Pharma Unveils Data Showing Superior Nasal Epinephrine Powder Deposition

Nasus Pharma Raises $15 Million in Private Placement of Unregistered Shares

Nasus Pharma Announces Closing of $15.0 Million Private Placement

THOMSON REUTERS

Press Release: Nasus Pharma Announces Pricing of $15.0 Million Private Placement

Nasus Pharma Ltd trading resumes

Amex Halt Add Info Lst 5.520000

THOMSON REUTERS

Nasus Pharma Calls March 5 Special Meeting to Boost Share Capital and Approve New Equity Incentives

Nasus Pharma Shareholders to Vote on U.S. Sub-Plan for 2019 Incentive Option Plan at Upcoming Meeting

Nasus Pharma Reports Strong Interim Phase 2 Data for Intranasal Epinephrine NS002

Nasus Pharma Reports Positive Interim Phase 2 Results for Intranasal Epinephrine NS002

Nasus Pharma Ltd - Interim Results Indicate Ns002 Shows Faster Absorption and Higher Peak Levels Than Epipen

THOMSON REUTERS

Nasus Pharma Announces Positive Interim Results From Phase 2 Clinical Study of Ns002 Intranasal Epinephrine Powder

THOMSON REUTERS

Nasus Pharma: Full Phase 2 Results Expected by End of Q1 2026; Pivotal Study Initiation Planned for Q4 of 2026

THOMSON REUTERS

Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development

Nasus Pharma CEO Issues 2025 Letter to Shareholders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NSRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":5.9,"timestamp":1771621200000,"preClose":5,"halted":0,"volume":9840,"hourTrading":{"tag":"盘后","latestPrice":5.97,"preClose":5.9,"latestTime":"19:42 EST","volume":4766,"amount":28732.8925,"timestamp":1771634578091,"change":0.07,"changeRate":0.011864,"amplitude":0.20339},"delay":0,"changeRate":0.18000000000000008,"floatShares":3982680,"shares":9063458,"eps":-0.211,"marketStatus":"Market Closed","change":0.9,"latestTime":"02-20 16:00:00 EST","open":5,"high":6.47,"low":5,"amount":58545.0234,"amplitude":0.294,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":5,"postHourTrading":{"tag":"盘后","latestPrice":5.97,"preClose":5.9,"latestTime":"19:42 EST","volume":4766,"amount":28732.8925,"timestamp":1771634578091,"change":0.07,"changeRate":0.011864,"amplitude":0.20339},"volumeRatio":3.6620764473642606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":3982680,"roa":"-106.39%","roe":"--","lyrEps":-0.217993,"volumeRatio":3.6620764473642606,"shares":9063458,"dividePrice":0,"high":6.47,"amplitude":0.294,"preClose":5,"low":5,"week52Low":4.9,"pbRate":"-12.40","week52High":9.9899,"institutionHeld":0,"latestPrice":5.9,"eps":-0.211,"divideRate":0,"volume":9840,"delay":0,"ttmEps":-0.211,"open":5,"prevYearClose":9.15,"prevWeekClose":5.9,"prevMonthClose":5.74,"prevQuarterClose":9.15,"fiveDayClose":5.6,"twentyDayClose":6.6288,"sixtyDayClose":7.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766120400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-02-20","current":-27.962085,"percent":0.9,"low":-51.389177,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"high":-25.573457,"avg":-41.124898,"sd":6.789298,"marketCap":58775295},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295}],"updateTime":1771776250821},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612027260","title":"Amex Halt  Add Info Lst 5.000000","url":"https://stock-news.laohu8.com/highlight/detail?id=2612027260","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612027260?lang=en_us&edition=fundamental","pubTime":"2026-02-20 22:45","pubTimestamp":1771598731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nAQN2LN5HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2612126407","title":"Nasus Pharma to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612126407","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612126407?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:00","pubTimestamp":1771592420,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL8k6RPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","NSRX","SG9999014013.SGD","BK4585","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2612128584","title":"Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2612128584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612128584?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:30","pubTimestamp":1771511411,"startTime":"0","endTime":"0","summary":"WSW, NY, February 19th, 2026, FinanceWire Not long ago, the notion that patients might swap the EpiPen experience for a needle-free alternative sti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nasus-pharma-is-targeting-a-validated-market-with-a-potentially-superior-intranasal-delivery-approach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nasus-pharma-is-targeting-a-validated-market-with-a-potentially-superior-intranasal-delivery-approach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX","SPN"],"gpt_icon":0},{"id":"2612425250","title":"Nasus Pharma Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612425250?lang=en_us&edition=fundamental","pubTime":"2026-02-19 04:15","pubTimestamp":1771445723,"startTime":"0","endTime":"0","summary":"15:12 EST Nasus Pharma (NSRX) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2612425149","title":"Amex Halt  Add Info Lst 6.400000","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425149","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612425149?lang=en_us&edition=fundamental","pubTime":"2026-02-19 04:12","pubTimestamp":1771445577,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nAQN2LMOOE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2612547452","title":"Nasus Pharma Unveils Data Showing Superior Nasal Epinephrine Powder Deposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2612547452","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612547452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333210,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. announced that data on its investigational intranasal epinephrine powder formulation, NS002, will be presented at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2. The presentations will cover the nasal deposition and stability of NS002, highlighting its potential for superior epinephrine absorption and robust formulation stability. The results have not yet been presented and are scheduled for March 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL6968xr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","NSRX","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD"],"gpt_icon":0},{"id":"2611524911","title":"Nasus Pharma Raises $15 Million in Private Placement of Unregistered Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611524911","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611524911?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987632,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd., a clinical-stage pharmaceutical company focused on innovative intranasal products, has announced the completion of a private placement of ordinary shares and warrants, raising approximately $15.0 million in gross proceeds. Citizens Capital Markets served as lead placement agent, with Laidlaw & Company  Ltd. as co-placement agent. The funds are expected to support the advancement of Nasus Pharma’s lead product candidate, NS002, a powder-based intranasal epinephrine, toward pivotal studies and a New Drug Application submission. The securities sold in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption. The company has agreed to file a registration statement with the SEC for the resale of the shares and warrants issued.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL9dkdLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","BK4007","NSRX","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2611415248","title":"Nasus Pharma Announces Closing of $15.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2611415248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611415248?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA47VPF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2610604464","title":"Press Release: Nasus Pharma Announces Pricing of $15.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610604464","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610604464?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:03","pubTimestamp":1770782580,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Feb. 10, 2026  -- Nasus Pharma Ltd.  , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it has entered into a securities purchase agreement  with certain institutional and accredited investors for a private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses.The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended , or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Pursuant to the Agreement, Nasus Pharma has agreed t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NSRX","BK4205","BK4516","BK4006","UK","BK4520","X","BK4233","BK4528","BK4007","BK4585"],"gpt_icon":0},{"id":"2608078608","title":"Nasus Pharma Ltd trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2608078608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608078608?lang=en_us&edition=fundamental","pubTime":"2026-02-04 04:00","pubTimestamp":1770148815,"startTime":"0","endTime":"0","summary":"14:59 EST Nasus Pharma (NSRX) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-ltd-trading-resumes-thefly-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-ltd-trading-resumes-thefly-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2608680224","title":"Amex Halt  Add Info Lst 5.520000","url":"https://stock-news.laohu8.com/highlight/detail?id=2608680224","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608680224?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:49","pubTimestamp":1770148157,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nAQN2LKIUG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2607054913","title":"Nasus Pharma Calls March 5 Special Meeting to Boost Share Capital and Approve New Equity Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2607054913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607054913?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:50","pubTimestamp":1769723441,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has issued an update. On January 29, 2026, Nasus Pharma Ltd. filed a report announcing it will hold a Special General...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-calls-march-5-special-meeting-to-boost-share-capital-and-approve-new-equity-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-calls-march-5-special-meeting-to-boost-share-capital-and-approve-new-equity-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX","EQR","BK4588","BK4215","BK4585"],"gpt_icon":0},{"id":"2607059120","title":"Nasus Pharma Shareholders to Vote on U.S. Sub-Plan for 2019 Incentive Option Plan at Upcoming Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607059120","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607059120?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:17","pubTimestamp":1769721461,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. has scheduled a Special General Meeting of Shareholders for March 5, 2026, where shareholders will vote on a proposal to approve the Sub-Plan for U.S. Persons to the Company's 2019 Incentive Option Plan. The board of directors recommends voting in favor of this proposal. Only shareholders of record as of February 9, 2026, are eligible to vote at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL1KVNBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2604207116","title":"Nasus Pharma Reports Strong Interim Phase 2 Data for Intranasal Epinephrine NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2604207116","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604207116?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:52","pubTimestamp":1768917140,"startTime":"0","endTime":"0","summary":"An update from Nasus Pharma Ltd. ( ($NSRX) ) is now available. On January 20, 2026, Nasus Pharma reported positive interim Phase 2 results for NS00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-reports-strong-interim-phase-2-data-for-intranasal-epinephrine-ns002?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-reports-strong-interim-phase-2-data-for-intranasal-epinephrine-ns002?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2604113193","title":"Nasus Pharma Reports Positive Interim Phase 2 Results for Intranasal Epinephrine NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113193","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113193?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914022,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. announced positive interim results from its Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. According to the company, interim data showed that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to the intramuscular EpiPen autoinjector. The study reported that 91% of participants reached the 100 pg/ml plasma threshold at 5 minutes with NS002, compared to 67% with EpiPen. NS002 was well-tolerated, with no serious adverse events reported, and demonstrated a pharmacodynamic response comparable to EpiPen. Full Phase 2 results are expected by the end of the first quarter of 2026, with a pivotal clinical study planned to begin in the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDLbJ9wrN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","BK4007","NSRX","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2604911329","title":"Nasus Pharma Ltd - Interim Results Indicate Ns002 Shows Faster Absorption and Higher Peak Levels Than Epipen","url":"https://stock-news.laohu8.com/highlight/detail?id=2604911329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604911329?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA5WGDP5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2604113946","title":"Nasus Pharma Announces Positive Interim Results From Phase 2 Clinical Study of Ns002 Intranasal Epinephrine Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113946?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA5WGDP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2604113291","title":"Nasus Pharma: Full Phase 2 Results Expected by End of Q1 2026; Pivotal Study Initiation Planned for Q4 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113291?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA5WGDP5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2593058487","title":"Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2593058487","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593058487?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408432,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. has expanded its collaboration agreements with Aptar France S.A.S. and AptarGroup Inc. to support the ongoing clinical development and planned commercialization of NS002, its investigational intranasal epinephrine powder formulation. The agreements provide Nasus Pharma with access to Aptar's commercially proven Unit Dose System technology, which is expected to accelerate NS002's path to market by leveraging established regulatory, manufacturing, and supply chain capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL8XfzFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4112","BK4007","NSRX","ATR","IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","BK4126","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2593480526","title":"Nasus Pharma CEO Issues 2025 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480526","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480526?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408400,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Dec.  22, 2025  (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\"Nasus Pharma\", “Nasus” or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209176/0/en/Nasus-Pharma-CEO-Issues-2025-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","BK4585","BK4520","X","BK4007","BK4006","NSRX","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}